These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38231269)

  • 21. Imaging genetics approach to Parkinson's disease and its correlation with clinical score.
    Kim M; Kim J; Lee SH; Park H
    Sci Rep; 2017 Apr; 7():46700. PubMed ID: 28429747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroimaging trials of Parkinson's disease progression.
    Seibyl J; Jennings D; Tabamo R; Marek K
    J Neurol; 2004 Oct; 251 Suppl 7():vII9-13. PubMed ID: 15505753
    [No Abstract]   [Full Text] [Related]  

  • 23. The Future of Brain Imaging in Parkinson's Disease.
    Helmich RC; Vaillancourt DE; Brooks DJ
    J Parkinsons Dis; 2018; 8(s1):S47-S51. PubMed ID: 30584163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mood and neural correlates of excessive daytime sleepiness in Parkinson's disease.
    Wen MC; Chan LL; Tan LCS; Tan EK
    Acta Neurol Scand; 2017 Aug; 136(2):84-96. PubMed ID: 28670700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Not Available].
    Prange S; Hermier M; Danaila T; Laurencin C; Thobois S
    Presse Med; 2017 Mar; 46(2 Pt 1):202-209. PubMed ID: 28040345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroimaging in Parkinson's disease: a future perspective.
    Brooks DJ
    Neurodegener Dis Manag; 2015; 5(2):105-8. PubMed ID: 25894874
    [No Abstract]   [Full Text] [Related]  

  • 27. Recent advances in biomarkers for Parkinson's disease focusing on biochemicals, omics and neuroimaging.
    Ren R; Sun Y; Zhao X; Pu X
    Clin Chem Lab Med; 2015 Sep; 53(10):1495-506. PubMed ID: 25581757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
    Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
    Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring diagnosis and imaging biomarkers of Parkinson's disease via iterative canonical correlation analysis based feature selection.
    Liu L; Wang Q; Adeli E; Zhang L; Zhang H; Shen D
    Comput Med Imaging Graph; 2018 Jul; 67():21-29. PubMed ID: 29702348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal intracortical diffusivity changes in de-novo Parkinson's disease: A promising imaging biomarker.
    Sampedro F; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
    Parkinsonism Relat Disord; 2019 Nov; 68():22-25. PubMed ID: 31621613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-accuracy Automated Diagnosis of Parkinson's Disease.
    Ozsahin I; Sekeroglu B; Pwavodi PC; Mok GSP
    Curr Med Imaging; 2020; 16(6):688-694. PubMed ID: 32723240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Research progress in the early diagnosis of Parkinson's disease.
    Xie L; Hu L
    Neurol Sci; 2022 Nov; 43(11):6225-6231. PubMed ID: 35948779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroimaging: current role in detecting pre-motor Parkinson's disease.
    Godau J; Hussl A; Lolekha P; Stoessl AJ; Seppi K
    Mov Disord; 2012 Apr; 27(5):634-43. PubMed ID: 22508281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cascaded Multi-Column RVFL+ Classifier for Single-Modal Neuroimaging-Based Diagnosis of Parkinson's Disease.
    Shi J; Xue Z; Dai Y; Peng B; Dong Y; Zhang Q; Zhang Y
    IEEE Trans Biomed Eng; 2019 Aug; 66(8):2362-2371. PubMed ID: 30582522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease.
    Seibyl J; Jennings D; Tabamo R; Marek K
    Minerva Med; 2005 Oct; 96(5):353-64. PubMed ID: 16227950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterned cortical atrophy in early Parkinson's Disease: The potential for unbiased, data driven neuroimaging to detect structural changes in de novo patients.
    Walsh RR
    Parkinsonism Relat Disord; 2018 May; 50():1-2. PubMed ID: 29643008
    [No Abstract]   [Full Text] [Related]  

  • 37. A task-specific cognitive domain decline is correlated with plasma and neuroimaging markers in patients with Parkinson's disease.
    Li CH; Chen TF; Peng PL; Lin CH
    J Neurol; 2022 Dec; 269(12):6530-6543. PubMed ID: 35965282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroimaging of Parkinson's disease by quantitative susceptibility mapping.
    Guan X; Lancione M; Ayton S; Dusek P; Langkammer C; Zhang M
    Neuroimage; 2024 Apr; 289():120547. PubMed ID: 38373677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroimaging approaches to cognition in Parkinson's disease.
    Montaser-Kouhsari L; Young CB; Poston KL
    Prog Brain Res; 2022; 269(1):257-286. PubMed ID: 35248197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease: A Review.
    Mitchell T; Lehéricy S; Chiu SY; Strafella AP; Stoessl AJ; Vaillancourt DE
    JAMA Neurol; 2021 Oct; 78(10):1262-1272. PubMed ID: 34459865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.